PRIA Logo™
119-hr-4191119th CongressWALLET

MAPS Act

Sponsored By: Representative Matsui, Doris O. [D-CA-7]

Introduced

Summary

Would create a federal framework to identify and reduce vulnerabilities in America's drug supply with a focus on an Essential Medicines List, risk assessments, and full supply‑chain mapping. The bill centers on three connected programs that together aim to spot shortage risks, foreign or single‑supplier dependencies, and national security or public health weak spots.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

4 provisions identified: 4 benefits, 0 costs, 0 mixed.

Map drug supply chains and risks

HHS would assess and map the supply chains for drugs on the essential list. It would check items with over 50% foreign reliance or a single supplier and review domestic capacity and advanced manufacturing. It would also flag public health and national security risks, including cyber threats, and consider Defense Production Act tools. Findings would be reported to Congress within 180 days and then yearly. Mapping progress would be reported within 18 months and then yearly.

National list of essential medicines

This bill would direct HHS to keep a national list of essential medicines and key ingredients. It would include drugs for chemical, biological, radiological, or nuclear emergencies, drugs at high risk of shortage, and drugs where a shortage would harm people with chronic conditions. HHS would update the list at least every 2 years. The first update would be due within 180 days after enactment and then published promptly.

Streamlined agency rules and definitions

The Secretary’s work on the essential medicines list would count toward duties in Executive Order 13944. The bill would also define key terms like advanced manufacturing, cybersecurity threat, drug, and who the Secretary is for this Act. These steps would cut duplicate paperwork and clarify how the law is applied.

Secure and share drug supply data

Agencies would be allowed to share needed supply-chain data for the risk and mapping work without violating 18 U.S.C. 1905. This would not change what counts as a trade secret or how FOIA applies. HHS would also need strong cybersecurity to prevent unauthorized access to shared data.

Sponsors & CoSponsors

Sponsor

Matsui, Doris O. [D-CA-7]

CA • D

Cosponsors

  • Rep. Crenshaw, Dan [R-TX-2]

    TX • R

    Sponsored 6/26/2025

  • Rep. Bacon, Don [R-NE-2]

    NE • R

    Sponsored 6/23/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation